What Translate Bio, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Hughes Owen | Director | Sep 14 | Open-market sale · S | −29,860 | $38.00 | −$1.13M | 0 |
| Renaud Ronald C Jr | Chief Executive Officer | Sep 14 | Open-market sale · S | −40,909 | $38.00 | −$1.55M | 0 |
| Renaud Ronald C Jr | Chief Executive Officer | Sep 14 | Open-market sale · S | −409,913 | $38.00 | −$15.6M | 0 |
| Renaud Ronald C Jr | Chief Executive Officer | Sep 14 | Open-market sale · S | −503,231 | $38.00 | −$19.1M | 0 |
| Burgess Paul D. | Chief Operating Officer, CLO | Sep 14 | Open-market sale · S | −71,833 | $38.00 | −$2.73M | 0 |
| Sanofi | 10% owner | Sep 14 | Open-market buy · P | +20,515,985 | $38.00 | +$780M | 75,668,031 |
| Sanofi | 10% owner | Sep 14 | Open-market buy · P | +51,467,612 | $38.00 | +$1.96B | 55,152,046 |
| Formela Jean Francois | Director | Sep 14 | Disclosed 10b5-1 sale · S | −2,055,063 | $38.00 | −$78.1M | 0 |
| Baupost Group LLC/MA | 10% owner | Sep 14 | Other Transaction · J | −18,044,239 | $38.00 | −$686M | 0 |
| Renaud Ronald C Jr | Chief Executive Officer | Apr 07 | Exercise / conversion · M | +9,026 | $7.39 | +$66.7K | 503,231 |
| Renaud Ronald C Jr | Chief Executive Officer, Pres. | Jan 14 | Exercise / conversion · M | +1 | $8.34 | +$8.34 | 494,205 |
| Renaud Ronald C Jr | Chief Executive Officer, Pres. | Jan 14 | Exercise / conversion · M | +5,638 | $7.39 | +$41.7K | 494,204 |
| Formela Jean Francois | Director | Dec 22 | Disclosed 10b5-1 sale · S | −2,700 | $25.88 | −$69.9K | 43,940 |
| Formela Jean Francois | Director | Dec 22 | Disclosed 10b5-1 sale · S | −79,865 | $25.04 | −$2M | 46,640 |
| Formela Jean Francois | Director | Dec 21 | Disclosed 10b5-1 sale · S | −56,536 | $25.50 | −$1.44M | 126,505 |
| Lynch Daniel | Director | Dec 17 | Gift · G | −100,000 | — | — | 221,825 |
| Renaud Ronald C Jr | Chief Executive Officer, Pres. | Nov 16 | Exercise / conversion · M | +3 | $8.34 | +$25 | 488,566 |
| Renaud Ronald C Jr | Chief Executive Officer, Pres. | Nov 16 | Exercise / conversion · M | +53,004 | $7.39 | +$392K | 488,563 |
| Formela Jean Francois | Director | Aug 27 | Open-market sale · S | −10,097 | $14.38 | −$145K | 3,833,122 |
| Formela Jean Francois | Director | Aug 26 | Open-market sale · S | −44,381 | $14.80 | −$657K | 3,843,219 |
Loading...
